Cardiovascular and Metabolic Diseases Animal Models
Cardiovascular and Metabolic Diseases Animal Model Services
Our in vivo pharmacology team is experienced with cardiovascular and metabolic disease model establishment and validation. In addition to in vivo metabolic models, in vivo organ damage models and standard ex vivo assays services, the following services are available:
- Enzyme assay: DPP4 activity assay
- Urine volume and urine glucose levels
- Liver lipid level
- Fecal neutral sterol and bile acid measurement
- Adipocyte size
- β-cell function (pancreatic α/β cell ratio & islet Size )
- Liver steatosis (fatty liver), Malonyl-CoA , ketone, cytokine
- Biomarker: Gene or protein expression, cytokines (IHC, ELISA, WB, PCR/qPCR)
- Aorta: Oil-Red-O staining
- Continuous metabolic /CNS data acquisition system
Capabilities
in vivo Metabolic Models
- T1D – STZ Diabetic model
- Diet-induced obesity, steatosis: HFD, HSD, gDIO, eDIO
- T2D – DIO/STZ diabetic model
- Mutant models
- Genetically modified models upon request
- Diet-induced hyperlipidemia
- Tg hyperlipidemia model – ApoA1
- GLP-1R humanized mouse
- PK/PD
in vivo Organ Damage Models
- Hypertension (SHR)
- Stroke
- NAFLD & NASH, liver fibrosis
- Acute liver injury
- Chronic kidney disease
- Diabetic nephropathy, hyperurecemia, renal failure
- PSC (bile duct ligation or DDC diet induction)
- Thyroidectomy, endometriosis, hypterlipidemia
- Anemia
- Heart failure, infarction
Standard ex vivo Assays
- Body weight, food/water consumption
- Blood glucose
- Lactate level
- oGTT, ITT
- Complete lipids profile
- Insulin, GLP-1, Leptin
- HbA1C, free fatty acids, ketones
- Blood chemistry profile
- Blood pressure (MBP, SBP & DBP, HR)
